GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (OTCPK:LBLTF) » Definitions » Forward PE Ratio

Lattice Biologics (Lattice Biologics) Forward PE Ratio : 0.00 (As of Apr. 29, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Lattice Biologics Forward PE Ratio?

Lattice Biologics's Forward PE Ratio for today is 0.00.

Lattice Biologics's PE Ratio without NRI for today is 0.00.

Lattice Biologics's PE Ratio for today is 0.00.


Lattice Biologics Forward PE Ratio Historical Data

The historical data trend for Lattice Biologics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Forward PE Ratio Chart

Lattice Biologics Annual Data
Trend
Forward PE Ratio

Lattice Biologics Quarterly Data
Forward PE Ratio

Competitive Comparison of Lattice Biologics's Forward PE Ratio

For the Medical Devices subindustry, Lattice Biologics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lattice Biologics's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Lattice Biologics's Forward PE Ratio falls into.



Lattice Biologics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Lattice Biologics  (OTCPK:LBLTF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Lattice Biologics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lattice Biologics (Lattice Biologics) Business Description

Traded in Other Exchanges
N/A
Address
512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (Lattice Biologics) Headlines

No Headlines